Compare FMC Corp (FMC) vs L3Harris Technologies Inc (LHX) Price & Performance

FMC Corporation (FMC) trades at $11.61, up 8.3% today, but remains in a challenging fundamental position with a net income margin of -72.93% and negative ROE of -80.78% for 2025. The company is actively restructuring, securing a $400 million minority investment from Tessenderlo Group and planning a $114 million property sale to reduce its $3.03 billion long-term debt. Technical indicators are bearish, with the stock trading near key support at $11. Recent news highlights progress on its new herbicide, rimisoxafen, including a regulatory submission to the EPA and a partnership with Corteva.

The outlook is cautious. While aggressive debt reduction and new product pipelines offer potential, deep losses and declining revenue pose significant risks. The analyst consensus is mixed (47.6% Buy, 50% Hold) with a $16 price target, suggesting modest upside if turnaround efforts succeed, but high execution risk remains the primary concern for investors.

LHX trades at $283.29, down 2.32% on the day, amid a bearish technical signal but strong fundamentals. The company has beaten EPS estimates for three consecutive quarters, with revenue growing to $21.87B in 2025 and net income reaching $1.61B. Recent contract wins from the U.S. Space Force and Army highlight ongoing defense demand, while analyst consensus remains strongly bullish with a $367.50 price target.

The outlook for LHX is positive given its record backlog and government contracts, though risks include execution on growth initiatives and defense budget volatility. With a P/E of 31.14, the stock trades at a premium to historical averages, but institutional support and dividend payments provide stability. Near-term performance hinges on Q2 2026 earnings due next.